The stock of Verastem Inc (NASDAQ:VSTM) closed at $3.72 gaining 3.33% in yesterday’s trading session. Verastem made the announcement regarding the positive results that were obtained from its Phase 3 DUO study. It was conducted in a bid to evaluate both the safety and the efficacy of duvelisib which happens to be its leukemia drug.
What followed was a sudden significant surge in its pre-market action, a matter that has been closely attributed to the series of changes that the company has been making in the recent times. Over the years, quite a large number of people around the globe have been struggling with the relapsed or chronic lymphocytic leukemia. Another large group has been suffering from the small lymphocytic lymphoma and the most recent reports indicate that these patients have started experiencing major improvements in health.
This study has indicated a 48% reduction in terms of the deaths associated with the condition. The Phase 3 DUO study had about 319 patients receive either atumumab monotherapy or the duvelisib 25mg orally and that was administered two times every day.
The Chief Medical Officer of Verastem, Diep Le opined. “CLL/SLL mostly affects elderly patients and many are unable or unwilling to be hospitalized or come into the clinic for frequent IV infusions. The CLL/SLL treatment landscape therefore is moving away from chemotherapies and toward more targeted, preferably oral regimens.”
He agreed that the remedy was indeed working when it came to helping patients live longer. However, he proceeded to outline that quite a large number remained intolerant to the therapy. He also laid great emphasis on the fact that it was critical for patients around the globe to consider using the new options.
According to him, Oral duvelisib happens to be the first PI3K inhibitor to showcase efficacy as a form of oral monotherapy. It is remarkable choice for the various patients having the progressed or relapsed.
Verastem has exuded much confidence outlining that it is still on track towards submitting the newest Drug Application to the U.S. Food and Drug Administrations and it might be doing that in the first quarter of the coming year.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: